Drug news
Viread(Gilead Sciences) and Kidney Disease risk
Viread (tenofovir) from Gilead Sciences one of the most commonly prescribed antiretroviral medications for HIV/AIDS, is associated with a significant risk of kidney damage and chronic kidney disease that increases over time, according to a study of more than 10,000 patients led by researchers at the San Francisco VA Medical Center (SFVAMC) and the University of California, San Francisco .
The researchers call for increased screening for kidney damage in patients taking the drug, especially those with other risk factors for kidney disease. In their analysis of comprehensive VA electronic health records, the study authors found that for each year of exposure to tenofovir, risk of protein in urine - a marker of kidney damage - rose 34 percent, risk of rapid decline in kidney function rose 11 percent and risk of developing chronic kidney disease rose 33 percent.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins